Although properly managing women with APS during pregnancy decreases both maternal and fetal morbidity and mortality, lack of standardization in lab testing can confuse clinicians. Complicating matters further, treatment can sometimes be controversial.
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More